SE9804001D0 - New process - Google Patents

New process

Info

Publication number
SE9804001D0
SE9804001D0 SE9804001A SE9804001A SE9804001D0 SE 9804001 D0 SE9804001 D0 SE 9804001D0 SE 9804001 A SE9804001 A SE 9804001A SE 9804001 A SE9804001 A SE 9804001A SE 9804001 D0 SE9804001 D0 SE 9804001D0
Authority
SE
Sweden
Prior art keywords
solvent
substance
treatment
water
formulations
Prior art date
Application number
SE9804001A
Other languages
English (en)
Swedish (sv)
Inventor
Mikael Bisrat
Mustafa Demirbueker
Saeed Moshashaee
Haakan Nyqvist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413378&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9804001(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804001A priority Critical patent/SE9804001D0/xx
Publication of SE9804001D0 publication Critical patent/SE9804001D0/xx
Priority to PT99963730T priority patent/PT1133284E/pt
Priority to CA002348084A priority patent/CA2348084C/en
Priority to US09/486,689 priority patent/US6461642B1/en
Priority to PCT/SE1999/002153 priority patent/WO2000030613A1/en
Priority to DE69920946T priority patent/DE69920946T3/de
Priority to ES99963730T priority patent/ES2228149T5/es
Priority to JP2000583497A priority patent/JP4616993B2/ja
Priority to AU20103/00A priority patent/AU767767B2/en
Priority to DK99963730T priority patent/DK1133284T4/da
Priority to AT99963730T priority patent/ATE278391T1/de
Priority to EP99963730A priority patent/EP1133284B2/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
SE9804001A 1998-11-23 1998-11-23 New process SE9804001D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process
EP99963730A EP1133284B2 (en) 1998-11-23 1999-11-22 A process for the preparation of crystalline particles
AT99963730T ATE278391T1 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel
US09/486,689 US6461642B1 (en) 1998-11-23 1999-11-22 Crystallization using supercritical or subcritical fluids
CA002348084A CA2348084C (en) 1998-11-23 1999-11-22 Crystallisation using supercritical or subcritical fluids
PT99963730T PT1133284E (pt) 1998-11-23 1999-11-22 Um processo para a preparacao de particulas cristalinas
PCT/SE1999/002153 WO2000030613A1 (en) 1998-11-23 1999-11-22 New process
DE69920946T DE69920946T3 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel
ES99963730T ES2228149T5 (es) 1998-11-23 1999-11-22 Un procedimiento para la preparacion de particulas cristalinas.
JP2000583497A JP4616993B2 (ja) 1998-11-23 1999-11-22 新しい製造方法
AU20103/00A AU767767B2 (en) 1998-11-23 1999-11-22 New process
DK99963730T DK1133284T4 (da) 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af krystallinske partikler

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process

Publications (1)

Publication Number Publication Date
SE9804001D0 true SE9804001D0 (sv) 1998-11-23

Family

ID=20413378

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process

Country Status (12)

Country Link
US (1) US6461642B1 (xx)
EP (1) EP1133284B2 (xx)
JP (1) JP4616993B2 (xx)
AT (1) ATE278391T1 (xx)
AU (1) AU767767B2 (xx)
CA (1) CA2348084C (xx)
DE (1) DE69920946T3 (xx)
DK (1) DK1133284T4 (xx)
ES (1) ES2228149T5 (xx)
PT (1) PT1133284E (xx)
SE (1) SE9804001D0 (xx)
WO (1) WO2000030613A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694686A5 (it) 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
ES2170008B1 (es) * 2000-08-25 2003-05-01 Soc Es Carburos Metalicos Sa Procedimiento para la precipitacion de particulas solidas finamente divididas.
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
JP2005511521A (ja) * 2001-10-10 2005-04-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 加圧ガス状流体による粉末処理
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
AU2003297367A1 (en) * 2002-12-19 2004-07-14 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials
WO2005013945A2 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
DK1701775T4 (da) * 2003-11-19 2012-07-23 Natex Prozesstech Gmbh Fremgangsmåde og proces til styring af temperatur-, tryk- og densitetsprofiler i processer med tætte fluider samt tilhørende apparat
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
EP2049086A2 (en) * 2006-08-09 2009-04-22 Glaxo Group Limited Process for manufacturing lactose
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
WO2009072950A1 (en) * 2007-12-07 2009-06-11 Xspray Microparticles Ab Method and arrangement for the production of particles
DE102008053618A1 (de) * 2008-10-29 2010-07-01 Karlsruher Institut für Technologie Verfahren zur Ausfällung von Salzen
ES2342140B1 (es) * 2008-12-30 2011-05-17 Consejo Superior Investigacion Procedimiento para la obtencion de micro- o nanoparticulas solidas
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
CN102327186A (zh) * 2011-09-30 2012-01-25 四川大学 一种采用超临界co2流体技术制备水溶性药物缓释微粒的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
PT1393721E (pt) 1997-03-20 2009-02-02 Schering Corp Forma de dosagem de aglomerados de pó

Also Published As

Publication number Publication date
EP1133284B1 (en) 2004-10-06
ES2228149T3 (es) 2005-04-01
CA2348084A1 (en) 2000-06-02
WO2000030613A1 (en) 2000-06-02
DE69920946T3 (de) 2009-02-26
EP1133284A1 (en) 2001-09-19
JP4616993B2 (ja) 2011-01-19
CA2348084C (en) 2009-01-06
ES2228149T5 (es) 2008-12-16
DK1133284T4 (da) 2008-11-10
US6461642B1 (en) 2002-10-08
DK1133284T3 (da) 2005-02-28
DE69920946T2 (de) 2005-08-25
ATE278391T1 (de) 2004-10-15
EP1133284B2 (en) 2008-08-06
AU767767B2 (en) 2003-11-20
AU2010300A (en) 2000-06-13
JP2002530318A (ja) 2002-09-17
DE69920946D1 (de) 2004-11-11
PT1133284E (pt) 2005-01-31

Similar Documents

Publication Publication Date Title
SE9804001D0 (sv) New process
EE200100275A (et) Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod
ATE168556T1 (de) Stabile budesonid-lösungen, verfahren zu deren herstellung sowie verwendung dieser lösungen als klistierzubereitungen und pharmazeutische schäume
MXPA03004883A (es) Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
IS8870A (is) Lyfjablanda sem felur í sér andrógen
EA199800531A1 (ru) Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона
ATE147976T1 (de) Protein nanomatrizen und verfahren zur herstellung
IL146659A0 (en) Porous drug matrices and method of manufacture thereof
MX9802734A (es) Nuevas formulaciones liquidas estables a base de paracetamol y su modo de preparacion.
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
FI972093A0 (fi) Jäteveden käsittelymenetelmä ja -laitos
ES2165936T3 (es) Procedimiento para la fabricacion de una formulacion terapeutica liposomal seca y solida, dispersable en agua, de administracion oral.
NO20030724D0 (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
ATE269057T1 (de) Arzneizubereitungen und deren herstellungsverfahren
JPS56106594A (en) Stabilizing method of plasminogen
AR008245A1 (es) Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
SE0203349D0 (sv) New use
NO20005725L (no) Biologisk aktiv sammensetning
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
HUP0401943A2 (hu) A 2alfa, 3alfa, 17alfa-trihidroxi-5alfa-androsztán-6-on alkalmazása a növényi fejlődés szabályozására a növényt érő stressz hatásának csökkentése által
RU2003115986A (ru) Способ лечения сенсоневральной тугоухости
RU2001125131A (ru) Способ лечения кератопатии
JPS5220991A (en) Activity regeneration method of active carbon for aqueous treatment an d its apparatus
UA43413C2 (uk) Спосіб одержання ін'єкційного засобу "ерихрозид" для лікування серцево-судинних захворювань